INTRODUCTION {#s1}
============

Alpha-fetoprotein (AFP) is a well-known embryonal serum protein that is mainly produced by fetal liver cells and yolk sac cells \[[@R1]\] and commonly serves as an important tumor marker for hepatocellular carcinoma or yolk sac tumors. However, many studies have revealed that several other kinds of tumor can produce AFP, among which gastric cancer is the most common \[[@R2]\]. Gastric cancer with a high level of AFP is termed α-fetoprotein--producing gastric cancer (AFPGC) \[[@R3]\]. AFPGC was first described by Bourreille et al. in 1970 \[[@R4]\], and has since been reported all over the world but mostly in Asia, with an incidence of 1.5%--7.1% among all gastric cancer cases \[[@R2], [@R3], [@R5]--[@R8]\].

AFPGC shows aggressive characteristics and is prone to liver and lymph node metastasis; accordingly, AFPGC is known to have an extremely poor prognosis \[[@R8]--[@R11]\]. However, the pathogenesis and the standardized treatment process of AFPGC remain elusive \[[@R3]\], and most previous studies are case reports. To improve understanding of AFPGC we retrospectively reviewed the clinicopathologic features of a consecutive series of 82 AFPGC patients in the First Affiliated Hospital, Nanjing Medical University, and investigated prognostic factors. We found that the serum AFP level of patients with AFPGC was significantly associated with tumor differentiation, and that patient gender, tumor differentiation, Lauren classification, and number of metastatic lymph nodes showed significant association with the four subtypes of AFPGC. The overall survival time of the 72 AFPGC patients with follow-up was 42.02 months, and the 3-year cumulative survival rate was 53.13%. Age, TNM stage, serum AFP level, and surgery were prognostic factors for overall survival; however, TNM stage was the only independent risk factor for prognosis of AFPGC.

RESULTS {#s2}
=======

General characteristics {#s2_1}
-----------------------

The 82 study patients with AFPGC have elevated serum AFP level, ranging from 20.5 ng/ml to more than 1,210 ng/ml with a median of 73.2 ng/ml. These patients included 62 males and 20 females with a median age of 62.5 years (range, 22--78 years). Regarding tumor location, 31 had tumor in the upper third of the stomach, 11 in the middle third, and 22 in the distal third, 17 patients had more than two thirds of the stomach affected, and one patient had gastric cancer with undetermined location.

Sixty-nine (84.15%) of our study patients underwent surgical treatment: of these, 54 patients underwent radical D2 gastrectomy including 36 cases of radical total gastrectomy, 16 cases of radical distal gastrectomy, and two cases of radical proximal gastrectomy. Six patients underwent curative-intent gastrectomy combined with other organ resection, including two cases of total gastrectomy with partial hepatectomy (for liver metastasis), two cases of distal gastrectomy with partial hepatectomy (for liver metastasis), one case of total gastrectomy with right ovariectomy (for ovarian metastasis), and one case of total gastrectomy with splenectomy (for N11 lymph node metastasis). Six patients with M1 disease underwent palliative gastrectomy, including two cases of total gastrectomy, one case of proximal gastrectomy, one case of distal gastrectomy, and two cases of gastrojejunostomy. Three cases were confirmed as T4b disease to pancreas and were treated with palliative total gastrectomy, palliative distal gastrectomy, and only laparotomy respectively.

Of the 82 patients with AFPGC, 24 cases (29.27%) were diagnosed with metastasis (M1) at the time of presentation including 17 cases of liver metastasis, two cases of ovarian metastasis, three cases of omentum metastasis, and two cases of other organ metastasis. Of these 24 cases, 12 did not undergo surgical intervention.

Thirty-four patients (47.22%) who underwent surgical treatment were followed up for serum AFP level. The serum AFP level decreased after radical surgical treatment in 28 patients and usually returned to a normal level in postoperative 1--3 months. Among six cases with persistently elevated postoperative serum AFP level, four patients underwent only palliative surgery and the underlying reason was not determined in the other two cases.

We analyzed the correlation between preoperative serum AFP level and clinicopathologic features in these AFPGC patients. As shown in Table [1](#T1){ref-type="table"}, the preoperative serum AFP level showed no significant association with gender, age, tumor location, TNM stage, or liver metastasis. However, the serum AFP level in patients with poorly differentiated tumor was significantly higher than that in patients with well-differentiated tumor (median 97.03 ng/ml *vs*. 36.38 ng/ml, *P*=0.0268). We also evaluated the relationship between the preoperative serum AFP and carcinoembryonic antigen (CEA) level, and found no significant association (*P*=0.1979).

###### Correlation of serum alpha-fetoprotein (AFP) level with clinicopathologic features in AFPGC patients

  Clinicopathological features   N    Serum AFP (ng/ml)\[median (range)\]   *P* value
  ------------------------------ ---- ------------------------------------- -----------
  Gender                                                                    0.070
   Male                          62   93.22(44.5625-823.825)                
   Female                        20   54.75(31.275-172.825)                 
  Age                                                                       0.909
   \<60yo                        26   72.00(39.375-339.45)                  
   ≥60yo                         56   73.20(39.65-439.875)                  
  Location                                                                  0.483
   Upper third                   31   54.10 (36.38-450.40)                  
   Middle third                  11   45.55 (28.25-310.80)                  
   Lower third                   23   94.16 (57.07-847.00)                  
   Two thirds or more            17   60.80 (50.40-476.10)                  
  Differentiation                                                           0.031
   Well differentiated           7    36.38 (24.00-46.30)                   
   Poorly differentiated         64   97.03 (46.425-622.375)                
  T stage                                                                   0.618
   T1                            5    39.20 (24.30-271.35)                  
   T2                            6    77.70 (41.9375-335.175)               
   T3                            3    74                                    
   T4                            54   83.34 (37.22-850.45)                  
  N stage                                                                   0.770
   N0                            8    45.925 (34.05-354.075)                
   N1                            11   74.00 (33.30-393.90)                  
   N2                            18   122.25 (49.95-850.45)                 
   N3                            30   83.34 (32.795-759.225)                
  M stage                                                                   0.811
   M0                            58   73.20 (35.825-418.825)                
   M1                            24   76.30 (46.425-223.15)                 
  TNM stage                                                                 0.301
   I\~II                         14   45.925 (30.075-208.35)                
   III                           42   96.09 (35.825-823.825)                
   IV                            24   76.30 (46.425-223.15)                 
  Liver metastasis                                                          0.567
   Yes                           17   83.00 (47.15-540.50)                  
   No                            65   72.40 (36.94-401.10)                  

Clinicopathologic characteristics of four morphologic subtypes of AFPGC {#s2_2}
-----------------------------------------------------------------------

According to previous studies \[[@R10], [@R12]--[@R15]\], the morphologic spectrum of AFPGC includes four subtypes: hepatoid type, fetal gastrointestinal type, yolk sac tumor-like type, and mixed type (Figure [1](#F1){ref-type="fig"}). On pathologic review, the 55 AFPGC patients with complete pathologic data consisted of 19 cases of hapatoid type (34.55%), 32 fetal gastrointestinal type (58.18%), 5 yolk sac tumor-like type (9.09%), and 8 mixed type (14.55%). We analyzed the correlation between subtype and clinicopathologic features, and further investigated the expression of AFP, vascular endothelial growth factor (VEGF), and CEA in these tumor tissues using immunohistochemistry. As shown in Table [2](#T2){ref-type="table"}, patient gender, tumor differentiation, Lauren classification, and number of lymph node (LN) metastases showed significant association with the four subtypes. However, TNM stage, liver metastasis, serum AFP level, and tumor AFP or CEA immunoreactivity did not present a correlation with these subtypes.

![Histologic subtypes of AFPGC\
**(A)** hepatoid type. Large polygonal hepatocyte-like cells with clear cytoplasm, resembling metastatic hepatocellular carcinoma but without biles. **(B)** fetal gastrointestinal type. Neoplastic glandular like early gut origin adenocarcinoma. **(C)** yolk sac tumor-like type. Reticular patterns formed by a loose network of sheets or nests with flat or cuboidal cells; **(D)** mixed type. Pleomorphic cells formed glandular clefts. Original magnification, ×100.](oncotarget-08-23817-g001){#F1}

###### Clinicopathologic characteristics of four subtypes of AFPGC

  Variables                        Hepatoid type(n=19)   Fetal gastrointestinal type(n=32)   Yolk sac tumor-like type(n=5)   Mixed type(n=8)   Chi-square   *P* value
  -------------------------------- --------------------- ----------------------------------- ------------------------------- ----------------- ------------ -----------
  Gender                                                                                                                                       10.143       0.010
   Male                            16                    26                                  4                               2                              
   Female                          3                     6                                   1                               6                              
  Age                                                                                                                                          2.118        0.595
   \<60yo                          8                     8                                   1                               3                              
   ≥60yo                           11                    24                                  4                               5                              
  Tumor location                                                                                                                               7.925        0.522
   Upper third                     7                     13                                  2                               2                              
   Middle third                    4                     4                                   0                               2                              
   Lower third                     5                     9                                   1                               0                              
  Two-thirds or more               3                     6                                   2                               4                              
  Histological differentiation                                                                                                                 7.860        0.047
   Well differentiated             0                     7                                   0                               0                              
   Poorly differentiated           19                    25                                  5                               8                              
  Lauren classification                                                                                                                        46.802       0.000
   Intestinal                      19                    32                                  0                               2                              
  Diffuse                          0                     0                                   5                               2                              
   Mixed                           0                     0                                   0                               4                              
  Depth of invasion                                                                                                                            9.489        0.264
   T1                              2                     3                                   0                               0                              
   T2                              3                     2                                   0                               1                              
   T3                              1                     0                                   0                               2                              
   T4                              13                    27                                  5                               5                              
  N status                                                                                                                                     8.282        0.462
   N0                              3                     3                                   0                               2                              
   N1                              3                     7                                   0                               1                              
   N2                              5                     11                                  0                               1                              
   N3                              8                     11                                  5                               4                              
  TNM stage                                                                                                                                    4.127        0.947
   I                               3                     3                                   0                               1                              
   II                              2                     3                                   0                               2                              
   III                             12                    20                                  4                               4                              
   IV                              2                     6                                   1                               1                              
  Lymphovascular invasion                                                                                                                      3.649        0.324
   Positive                        10                    9                                   2                               4                              
   Negative                        9                     23                                  3                               4                              
  Nerve invasion                                                                                                                               3.854        0.272
   Positive                        3                     8                                   3                               2                              
   Negative                        16                    24                                  2                               6                              
  Liver metastasis                                                                                                                             1.318        0.803
   Yes                             2                     5                                   0                               0                              
   No                              17                    27                                  5                               8                              
  Serum AFP level                                                                                                                              4.990        0.167
   \<200ng/ml                      8                     23                                  3                               6                              
   ≥200ng/ml                       11                    9                                   2                               2                              
  AFP immunoreactivity in tumor                                                                                                                3.234        0.354
   -                               12                    25                                  5                               7                              
   +\~++                           7                     7                                   0                               1                              
  VEGF immunoreactivity in tumor                                                                                                               2.543        0.466
   -\~+                            10                    23                                  4                               6                              
   ++                              9                     9                                   1                               2                              
  CEA immunoreactivity in tumor                                                                                                                10.945       0.065
   -                               12                    8                                   1                               1                              
   +                               4                     13                                  1                               4                              
   ++\~+++                         3                     11                                  3                               3                              

  Variables                 Hepatoid type(n=19)   Fetal gastrointestinal type(n=32)   Yolk sac tumor-like type(n=5)   Mixed type(n=8)   *F* value   *P* value
  ------------------------- --------------------- ----------------------------------- ------------------------------- ----------------- ----------- -----------
  Average tumor size (cm)   5.58±2.957            5.55±2.377                          8.80±4.087                      7.36±5.344        2.124       0.107
  LN harvest                27.11±14.541          24.69±11.893                        31.00±8.803                     32.50±14.283      0.992       0.403
  No. of LN metastasis      8.95±9.600            7.75±8.394                          21.60±7.403                     9.25±8.598        3.648       0.017
  Serum AFP (ng/ml)         525.30±494.093        275.05±411.640                      513.86±595.921                  153.26±227.547    2.112       0.108
  Serum CEA (ng/ml)         23.72±48.241          75.22±165.076                       3.65±1.279                      11.47±14.125      0.856       0.473

Survival analysis {#s2_3}
-----------------

Although all patients received follow-up, 10 patients (12.2%) were lost to follow-up. As shown in Figure [2A](#F2){ref-type="fig"}, the overall survival time (OS) of the remaining 72 patients was 1--69 months (mean 42.02 months) and the 3-year cumulative survival rate of the 72 patients was 53.13%.

![Survival analysis for AFPGC patients\
The mean overall survival (OS) of the 72 patients was 42.02 months, and the 3-year cumulative survival rate was 53.13% **(A)**, and surgical treatment showed significant beneficial effects on OS of 72 AFPGC patients (**(B)**, *P*=0.001). Compared with palliative surgery, radical surgery and curative-intent surgery produced significant survival benefits for 55 AFPGC patients with complete clinicopathologic data (**(C)**, *P*=0.001). However, surgical treatment did not produce survival benefit for 21 AFPGC patients with synchronous M1 disease (**(D)**, *P*=0.131), and curative-intent surgery also did not have survival advantage over palliative surgery in these M1 patients (**(E)**, *P*=0.524).](oncotarget-08-23817-g002){#F2}

The survival time of the surgery group (including radical gastrectomy, curative-intent gastrectomy combined with other organ resection, palliative gastrectomy, gastrojejunostomy, and laparotomy) was 1--69 months (mean 45.43 months) and the 3-year survival rate was 58.10%; in contrast, the survival time for the non-surgery group was only 4--28 months (mean 12.85 months) (Figure [2B](#F2){ref-type="fig"}, *P*=0.001). Furthermore, radical surgery and curative-intent surgery could produce significant survival benefits for 55 AFPGC patients with complete clinicopatholigic data with comparison to palliative surgery (Figure [2C](#F2){ref-type="fig"}, *P*=0.001). For 21 patients with synchronous M1 disease who had complete follow-up data there was no survival benefit from surgical treatment; the survival time was 4--32 months (mean 22.08 months) in the surgery group and 3--28 months (mean 12.32 months) in the non-surgery group (Figure [2D](#F2){ref-type="fig"}, *P*=0.131). Moreover curative-intent surgery for M1 disease did not show a survival advantage over palliative surgery (mean 25.00 months *vs*. 20.33 months, *P*=0.524) (Figure [2E](#F2){ref-type="fig"}).

The Kaplan--Meier method and log-rank test for 72 patients showed significant survival differences according to age, TNM stage (especially M0 *vs*. M1 and presence *vs*. absence of liver metastasis), and surgery (Table [3](#T3){ref-type="table"}). Similar results were observed for the 55 AFPGC patients with complete pathologic data and tests in this subgroup indicated that serum AFP level (\<200 ng/ml *vs*. ≥200 ng/ml) was a prognostic factor for overall survival (*P*=0.030) (Table [4](#T4){ref-type="table"}). However, multivariate Cox regression analysis showed that only TNM stage was an independent risk factor for prognosis in AFPGC (Table [5](#T5){ref-type="table"}).

###### Prognostic factors for overall survival analyzed by the Kaplan--Meier method in 72 AFPGC patients with follow-up

  Variables                        Total No.   No. of events   Means for survival time (months)   Chi-square   *P* value                     
  -------------------------------- ----------- --------------- ---------------------------------- ------------ ----------- -------- -------- -------
  Gender                                                                                                                            2.073    0.150
   Male                            56          19              43.814                             4.377        35.235      52.394            
   Female                          16          8               34.222                             7.162        20.184      48.260            
  Age                                                                                                                               4.047    0.044
   \<60yo                          20          11              27.908                             6.268        15.621      40.194            
   ≥60yo                           52          16              46.178                             4.229        37.889      54.467            
  Location                                                                                                                          2.625    0.453
   Upper third                     27          9               37.137                             6.631        24.140      50.133            
   Middle third                    9           2               49.733                             8.064        33.929      65.538            
   Lower third                     22          10              39.871                             6.468        27.193      52.549            
   Two thirds or more              14          6               27.136                             5.564        16.230      38.041            
  Differentiation                                                                                                                   0.035    0.851
   Well differentiated             7           2               38.286                             6.754        25.047      51.524            
   Poorly differentiated           55          19              44.712                             4.300        36.283      53.140            
  Lauren classification                                                                                                             1.469    0.480
   Diffuse type                    4           2               20.750                             11.438       0.000       43.169            
   Intestinal type                 47          14              47.726                             4.567        38.774      56.678            
   Mixed type                      4           1               17.500                             0.354        16.807      18.193            
  M stage                                                                                                                           12.245   0.000
   M0                              51          14              49.321                             4.304        40.884      57.757            
   M1                              21          13              17.904                             2.936        12.150      23.658            
  TNM stage                                                                                                                         14.756   0.001
   I\~II                           14          1               64.143                             4.680        54.969      73.317            
   III                             35          12              44.620                             4.956        34.906      54.335            
   IV                              21          13              17.904                             2.936        12.150      23.658            
  Liver metastasis                                                                                                                  6.420    0.011
   Yes                             16          9               18.503                             3.496        1.651       25.354            
   No                              56          18              46.288                             4.225        38.007      54.570            
  Vascular or lymphatic invasion                                                                                                    0.020    0.887
   Yes                             22          7               48.038                             6.492        35.313      60.763            
   No                              35          11              42.711                             4.585        33.723      51.698            
  Nerve invasion                                                                                                                    0.314    0.575
   Yes                             14          5               42.151                             7.373        27.699      56.603            
   No                              43          13              47.450                             4.706        38.227      56.674            
  Serological AFP level                                                                                                             1.683    0.195
   \<200ng/ml                      47          14              47.886                             4.695        38.683      57.088            
   ≥200ng/ml                       25          13              34.348                             5.548        23.474      45.223            
  Surgery                                                                                                                           22.052   0.000
   Radical surgery                 47          11              52.110                             4.283        43.716      60.504            
   Curative-intent surgery         4           2               25.000                             8.573        8.197       41.803            
   Palliative surgery              9           7               16.333                             3.668        9.143       23.523            
   No surgery                      12          7               12.854                             3.388        6.213       19.495            

###### Prognostic factors for overall survival analyzed by the Kaplan--Meier method in 55 AFPGC patients with complete clinicopathologic data

  Variables                        Total No.   No. of events   Means for survival time (months)   Chi-square   *P* value                     
  -------------------------------- ----------- --------------- ---------------------------------- ------------ ----------- -------- -------- -------
  Gender                                                                                                                            0.187    0.666
   Male                            43          13              46.749                             4.825        37.291      56.206            
   Female                          12          4               43.562                             7.922        28.035      59.090            
  Age                                                                                                                               5.431    0.020
   \<60yo                          14          8               29.785                             6.943        16.176      43.393            
   ≥60yo                           41          9               49.255                             3.990        41.434      57.075            
  Location                                                                                                                          4.070    0.254
   Upper third                     21          7               31.310                             3.321        24.801      37.818            
   Middle third                    8           1               55.200                             6.977        41.526      68.874            
   Lower third                     14          4               51.016                             7.394        36.524      65.508            
   Two thirds or more              12          5               28.333                             5.841        16.884      39.783            
  Differentiation                                                                                                                   0.000    0.995
   Well differentiated             7           2               38.286                             6.754        25.047      51.524            
   Poorly differentiated           48          15              47.041                             4.561        38.100      55.981            
  Lauren classification                                                                                                             1.469    0.480
   Diffuse type                    4           2               20.750                             11.438       0.000       43.169            
   Intestinal type                 47          14              47.726                             4.567        38.774      56.678            
   Mixed type                      4           1               17.500                             0.354        16.807      18.193            
  Morphologic subtype                                                                                                               2.589    0.459
   Hapatiod                        15          3               55.780                             6.794        42.463      69.097            
   fetal gastrointestinal          30          11              36.780                             3.988        28.963      44.596            
   yolk sac tumor-like             4           2               20.750                             51.438       0.000       43.169            
   mixed                           6           1               51.500                             9.959        31.980      71.020            
  M stage                                                                                                                           6.089    0.014
   M0                              47          12              50.468                             4.461        41.725      59.211            
   M1                              8           5               19.813                             4.919        10.172      29.453            
  TNM stage                                                                                                                         8.329    0.016
   I\~II                           14          1               64.143                             4.680        54.969      73.317            
   III                             33          11              42.532                             4.747        33.229      51.835            
   IV                              8           5               19.813                             4.919        10.172      29.453            
  Liver metastasis                                                                                                                  3.388    0.066
   Yes                             7           4               21.786                             5.270        11.457      32.115            
   No                              48          13              49.518                             4.466        40.764      58.272            
  Vascular invasion                                                                                                                 0.012    0.911
   Yes                             20          6               49.261                             6.723        36.084      62.438            
   No                              35          11              42.711                             4.585        33.723      51.698            
  Nerve invasion                                                                                                                    0.036    0.849
   Yes                             13          4               44.962                             7.482        30.297      59.626            
   No                              42          13              46.495                             4.855        36.980      56.011            
  AFP immunoreactivity in tumor                                                                                                     0.619    0.431
   -                               42          14              44.952                             5.029        35.095      54.809            
   +, ++                           13          3               41.046                             5.182        30.890      51.202            
  CEA immunoreactivity in tumor                                                                                                     0.144    0.931
   -                               20          6               47.874                             6.993        34.168      61.579            
   +                               20          6               40.626                             4.714        31.386      49.866            
   ++, +++                         15          5               43.018                             7.079        29.144      56.893            
  VEGF immunoreactivity in tumor                                                                                                    0.084    0.773
   -, +                            38          11              48.209                             5.158        38.100      58.318            
   ++                              17          6               36.536                             4.715        27.295      45.776            
  Serum AFP level                                                                                                                   4.724    0.030
   \<200ng/ml                      34          6               56.884                             4.492        48.079      65.688            
   ≥200ng/ml                       21          11              30.739                             4.031        22.838      38.640            
  Surgery                                                                                                                           16.847   0.000
   Radical surgery                 45          10              52.537                             4.426        43.861      61.212            
   Curative-intent surgery         4           2               25.000                             8.573        8.197       41.803            
   Palliative surgery              6           5               12.667                             3.970        4.886       20.447            

###### Multivariate analysis by the Cox model

  Clinicopathological factors   Covariate Means   *P* value   RR       95% CI for *RR*   
  ----------------------------- ----------------- ----------- -------- ----------------- --------
  Age                           0.743             0.133       0.534    0.236             1.210
  TNM stage                                       0.002                                  
   III vs I\~II                 0.500             0.298       3.023    0.376             24.301
   IV vs I\~II                  0.300             0.021       11.441   1.433             91.359
  Serum AFP                     0.343             0.065       2.179    0.953             4.983
  Surgery                       0.157             0.080       3.088    0.873             10.926

*RR*: relative risk.

DISCUSSION {#s3}
==========

Alpha-fetoprotein--producing gastric cancer is a relatively rare form of gastric cancer. In the present study AFPGC accounted for approximately 1.95% of all gastric cancers, which is similar to previous reports \[[@R2], [@R3], [@R5]--[@R8]\]. Van der Veek et al. \[[@R17]\] proposed that AFP values greater than 500 ng/ml are unlikely to be due to benign conditions, but only 18.29% (15/82) of AFPGC patients in the present series met this criterion. More importantly, among the AFPGC patients who were followed for serum AFP level, serum AFP level decreased rapidly after radical operation but remained high level after palliative surgery, strongly suggesting that AFP was produced by gastric cancer cells \[[@R2]\]. In this study, serum AFP level was significantly associated with tumor differentiation; however, no correlation with metastasis or liver metastasis was found \[[@R11]\].

Liver metastasis is a characteristic feature of AFPGC, occurring in 33%--72% of all AFPGC cases \[[@R9], [@R17]\]. Twenty-four patients (29.27%) in our study were diagnosed as synchronous metastasis, and most of these were liver metastasis, but we did not obtain details of metachronous liver metastasis or other metastasis during follow-up. Metachronous liver metastasis may occur in approximately 50% of patients who undergo curative resection of the tumor within a year after surgery \[[@R17], [@R18]\], and elevation of serum AFP level may be detected prior to appearance of symptoms and imaging detection. Therefore, AFPGC patients should be carefully observed for early detection and treatment of possible recurrent disease by measuring the serum AFP levels as a follow-up marker \[[@R9]\].

AFPGC can be divided into four morphologic subtypes. The hepatoid type and the yolk sac tumor-like type are derived from liver cell metaplasia and yolk sac cell metaplasia of common poorly differentiated medullary adenocarcinoma, respectively, whereas the fetal gastrointestinal type appears to be imitation of fetal gastrointestinal epithelium by common tubular adenocarcinoma \[[@R12]\]. Unlike previous reports \[[@R10], [@R12]\], the hepatoid type only accounted for 34.55% of the AFPGC cases in this study whereas more than half of our cases were the fetal gastrointestinal type. Tsung proposed that the criterion for diagnosing AFPGC is positive staining of AFP in the primary lesion by immunohistochemical methods \[[@R6]\]. However, the incidence of AFP-positive expression in this study was only 27.27% (Table [2](#T2){ref-type="table"}, 15/55), which was lower than that in other studies \[[@R10], [@R15], [@R19]\]. The expression of VEGF and CEA was also evaluated by immunohistochemistry, and our results indicated that AFP immunoreactivity was more common in the hepatoid type (Table [2](#T2){ref-type="table"}, 7/12, 36.84%) whereas CEA was more common in the fetal gastrointestinal type (Table [2](#T2){ref-type="table"}, 24/32, 75%), which is consistent with findings of previous studies \[[@R10], [@R17]\]. There were no significant differences in AFP, VEGF, and CEA expression among these four morphologic subtypes. All hepatoid type AFPGCs were poorly differentiated and had a higher incidence of lymphovascular invasion indicating that the hepatoid type is highly malignant \[[@R12]\], although there was no survival difference among the four subtypes. This study also showed that the yolk sac tumor-like type of AFPGC might be the most detrimental type; all tumors of this type were poorly differentiated and diffuse type of Lauren classification and had the highest number of metastatic lymph nodes. Wang et al. \[[@R10]\] also revealed that the yolk sac tumor-like type AFPGC had the worst prognosis among the four subtypes although no significant survival difference was found.

AFPGC has been considered to have unfavorable long-term survival, mainly due to the higher incidence of liver metastasis and lymphovascular invasion \[[@R9], [@R20]\]. In this study, the mean survival time was 42.02 months and the 3-year cumulative survival rate was 53.13%. Shibata et al. reported that the 5-year survival rate post-curative resection is only 8.3% \[[@R9]\]. The mechanisms underlying the poor prognosis are not well understood although AFP has been reported to have a suppressive effect on lymphocyte transformation \[[@R20]\], to enhance tumor cell proliferation through the HGF and c-Met pathway \[[@R9], [@R21]\], and to increase angiogenesis via VEGF expression \[[@R22], [@R23]\].

In the present report, patient age, TNM stage, and surgical treatment were found to be associated with overall survival. It is easily understood that young AFPGC patients are prone to a more detrimental prognosis. Metastatic diseases, especially liver metastasis, and advanced TNM stage were significantly negatively correlated with survival time, consistent with many previous reports \[[@R10], [@R11]\]. It is interesting that serum AFP level was a risk factor for survival in a subgroup of these patients, and the mean survival time of patients with AFP level greater than 200 ng/ml was shorter than that in patients with AFP level lower than 200 ng/ml (Table [4](#T4){ref-type="table"}). To our best knowledge, this is the first report of a significant association between serum AFP levels and overall survival in AFPGC patients. More than 80% of these patients underwent surgical treatment. Surgical treatment, especially radical surgery and curative-intent surgery, could produce survival advantages. However, surgical treatment for M1 disease did not present a survival benefit and curative-intent surgery was also not favorable for these patients, indicating that it will be important to develop a novel effective multimodal therapy for AFPGC \[[@R6], [@R9]\]. However, multivariate analysis indicated that only TNM stage was an independent risk factor for prognosis in AFPGC, consistent with previous studies \[[@R10]\].

Obviously, limited knowledge and limited successful treatment options exist for AFPGC \[[@R17]\]. It has gradually become recognized that AFPGC is quite different from the conventional type of gastric cancer. Recently, several studies have been conducted on AFPGC with the aim of improving the outcome of AFPGC patients. He et al. \[[@R8]\] investigated the differential expression of proteins between AFPGC and AFP non-producing gastric cancer and found that high level expressions of XIAP and IGF-Irβ in tumor tissues were independent factors for poor prognosis in AFPGC patients, and that AFPGC may be separated into two subgroups with involvement of a distinct set of signaling pathways based on a risk model of XIAP and IGF-Irβ expression and TNM stage. Shimakata et al. \[[@R7]\] investigated expression levels of a panel of solute carrier transporters (SLC) in AFPGC and conventional gastric cancer and proposed that patients with AFPGC may potentially benefit from gemcitabine/fluoropyrimidine combination chemotherapy. Better understanding of AFPGC at the cellular and molecular levels will aid the development of individualized therapy for AFPGC \[[@R3], [@R6]\].

In conclusion, AFPGC is a rare, unique, and heterogeneous entity, and its proper identification and treatment remain a challenge. The present study helps us understand AFPGC; however, greater attention must be paid to AFPGC to improve patient care and the dismal prognosis.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

Approximately 4,200 patients with primary gastric adenocarcinoma were diagnosed and treated in the First Affiliated Hospital, Nanjing Medical University from January 2010 to May 2016. We searched for patients with elevated serum alpha-fetoprotein (AFP) level on admission among these cases. Serum AFP level was determined by ELISA, and a concentration greater than 20 ng/ml was considered elevated. Patients with abnormal liver function or with liver diseases such as acute or chronic hepatitis, cirrhosis, fatty liver, alcoholic liver, and primary liver cancer were excluded. A total of 82 patients (1.95%) were confirmed as alpha-fetoprotein--producing gastric cancer (AFPGC) and were enrolled in the present study. All patients were diagnosed pathologically according to the AJCC criteria (7th ed., 2010). The clinicopathologic data of these enrolled patients were collected retrospectively and the patients received follow-up for survival by telephone or subsequent consultation with a cut-off date of October 2016. The follow up time was 4--70 months (median: 27.5 months). Patients provided their written informed consent. Samples were stored in the hospital database for studies. This study was approved by the Nanjing Medical University Institutional Review Board, and complied with the Helsinki Declaration.

Tissue array and immunohistochemistry {#s4_2}
-------------------------------------

All pathologic data of the enrolled patients were reviewed independently by two experienced pathologists for histologic classification according to previous reports \[[@R10], [@R13]\].

Paraffin-embedded formalin-fixed tissues were obtained and re-embedded in an arrayed master block. The Beecher Instruments arraying device (Sun Prairie, WI, USA) was used to produce circular sample spots 1.0 mm in diameter. Immunohistochemistry was performed according to standard protocols. Briefly, 4-μm sections were deparaffinized in xylene and rehydrated in graded ethanol. Antigen retrieval was achieved by boiling the sections in 10 mM citrate buffer (pH 6.0) for 10 min in a pressure cooker. The sections were then sequentially blocked with 3% hydrogen peroxide/methanol for 10 min and with non-immune serum for 10 min. The sections were incubated overnight at 4°C with primary antibodies against AFP, CEA, and VEGF (Fuzhou Maixin Biotechnology, Fuzhou, China). Negative controls were prepared by omitting the primary antibody. After a wash with phosphate-buffered saline (PBS), the sections were incubated with biotin secondary antigen for 15 min at 37°C and then the chromogen was developed for 5 min with liquid 3,3′-diaminobenzidine. Nuclei were counterstained with hematoxylin.

The staining was evaluated by two pathologists on the basis of the percentage of stained cells and staining density. The grades for the percentage of stained cells ranged from 0 to 4 (0, unstained cells; 1, 1--10% stained cells; 2, 11--50% stained cells; 3, 51--80% stained cells; 4, 81--100% stained cells). The grades for staining density ranged from 0 to 3 (0, unstained cells; 1, slightly stained cells; 2, moderately stained cells; 3, highly stained cells). The two scores were multiplied, resulting in the following levels of immunohistochemical staining: 0 points, −; 1--4 points, +; 5--8 points, ++; and 9--12 points, +++.

Statistical analysis {#s4_3}
--------------------

Statistical analysis was performed using SPSS 22.0 software (SPSS Inc., IL, USA). Mann--Whitney U test and Kruskal--Wallis test were used to analyze the relationship between serum AFP level and clinicopathologic features. The Chi-square Test, Fisher Probabilistic Methods, and ANOVA were used to analyze the relationships between the four subtypes of AFPGC and clinicopathologic features. The clinicopathologic factors were analyzed by the Kaplan--Meier method and compared by the log-rank test. The Cox model was also used to analyze the prognostic factors in a multivariate analysis. The observed end point was death. All tests were two-sided. A *P* value \<0.05 was considered statistically significant.

The authors are grateful to all doctors at the relevant departments for their clinical practice on the enrolled patients.
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